Claims for Patent: 12,208,102

Summary for Patent: 12,208,102

Title:	Methods of treating cancer
Abstract:	The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a compound of the formula 1. The invention described herein also relates to methods of treating PSMA-expressing cancers with a compound of the formula 1 inpatients where stable disease results after treatment with the compound of the formula 1.
Inventor(s):	Alison A. Armour
Assignee:	Endocyte Inc
Application Number:	US17/047,778
Patent Claims:	1. A method for treating a cancer in a patient in need of such treatment comprising, administering to the patient a therapeutically effective amount of a composition comprising a compound of the formula 1 wherein the compound is complexed with Lu; wherein the composition provides about 7.4 GBq of radioactivity per administration; wherein the composition is administered on a schedule of once per every 4 to 6 weeks for 4 to 6 cycles, wherein the cancer is metastatic castration-resistant prostate cancer, and wherein the patient has been treated with a prior androgen axis systemic treatment. 2. The method of claim 1, wherein the composition is administered in a parenteral dosage form. 3. The method of claim 2, wherein the parenteral dosage form is selected from the group consisting of intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, and intrathecal. 4. The method of claim 3, further comprising imaging PSMA expression by the cancer. 5. The method of claim 4, wherein the imaging occurs before the step of administering. 6. The method of claim 5, wherein the imaging is performed by imaging and wherein the imaging is selected from the group consisting of SPECT imaging or PET imaging. 7. The method of claim 6, further comprising determining the PSMA status of the patient by imaging. 8. The method of claim 7, wherein the imaging in the step of determining is SPECT imaging. 9. The method of claim 8, wherein the PSMA status of the patient correlates with a clinical benefit to the patient selected from the group consisting of inhibition of tumor growth, stable disease, a partial response, and a complete response. 10. The method of claim 1, wherein the prior androgen axis systemic treatment is selected from the group consisting of abiraterone, orteronel, galeterone, seviteronel, apalutamide, enzalutamide, and combinations thereof. 11. The method of claim 10, wherein the patient has been treated with a prior treatment selected from the group consisting of chemotherapeutic agent, surgery, radiation therapy, immunotherapy, photodynamic therapy, stem cell therapy, and hyperthermia. 12. The method of claim 11, wherein the prior treatment is selected from the group consisting of palifosfamide, 5-fluorouracil, capecitabine, pemetrexed, cisplatin, carboplatin, gemcitabine, paclitaxel, vinorelbine, eribulin, docetaxel, cyclophosphamide, and doxorubicin, regorafinib. 13. The method of claim 1, wherein the composition is administered in combination with a second treatment. 14. The method of claim 13, wherein the second treatment is an androgen axis systemic treatment selected from the group consisting of abiraterone, orteronel, galeterone, seviteronel, apalutamide, enzalutamide, and combinations thereof. 15. The method of claim 13, wherein the second treatment is external beam radiation therapy (EBRT). 16. The method of claim 1, wherein the composition provides a total dose of about 29.6 to about 44 GBq of radioactivity. 17. A method for treating prostate cancer in a patient in need of such treatment comprising, administering to the patient a therapeutically effective amount of a composition comprising a compound of the formula 1 wherein the compound is complexed with 177Lu; wherein the composition provides about 7.4 GBq of radioactivity per administration; wherein the composition is administered on a schedule of once per every 4 to 6 weeks for 4 to 6 cycles such that the method provides a total dose of about 29.6 to about 44 GBq of radioactivity; and wherein the patient has been treated with at least one prior androgen axis systemic treatment.